Back to results
US 12,213,967 B2Granted
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
AssigneeDeciphera Pharmaceuticals, LLC
InventorsMichael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Life of this patent
Estimating the term…
Abstract
Provided herein are low impurity compositions comprising a compound represented which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.
Claims11
A solid dispersion comprising a compound represented by Formula (I):
- and hydroxypropylmethyl cellulose acetate succinate, wherein the compound is present with a purity of greater than 90% as determined by HPLC.
A pharmaceutical composition comprising:
- a solid dispersion comprising:
- a compound represented by Formula (I) or pharmaceutically acceptable salt thereof,
- and hydroxypropylmethyl cellulose acetate succinate;
- and
- wherein the pharmaceutical composition comprises one or more anilinic substances present in an amount equal to or less than about 10% by weight based on the weight of the compound of Formula (I) present in the composition.
2 more elements
A pharmaceutical composition, comprising:
- (i) a solid dispersion, wherein the solid dispersion comprises:
- (a) a compound represented by Formula (I):
- and
- (b) hydroxypropyl methyl cellulose acetate succinate.
1 more element
A pharmaceutical composition, comprising:
- a solid dispersion comprising:
- (a) 50 mg of a compound represented by Formula (I):
- and
- (b) hydroxypropyl methyl cellulose acetate succinate.
1 more element
Dependencies are inferred from the claim text.